linjc16/ctgov huggingface dataset:
Relation of Implantation Site to Placental Site

Study Overview
=================
Brief Summary
-----------------
Trans vaginal ultrasound with a partially full bladder will be done at gestational age earlier than 10 weeks to assess the site of intrauterine gestational sac to the endometrial cavity and the distance between the implantation site and the internal cervical os . Doppler assessment of the retrochorionic blood flow at the area behind the maximum chorionic tissue to detect resistance index.

Official Title
-----------------
Relation of Implantation Site to Placental Site With or Without Cesarean Section Scar

Conditions
-----------------
Placenta Implantation Site

Intervention / Treatment
-----------------
* Device: Transvaginal ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single intrauterine pregnancy Gestational age less than 10 weeks Exclusion Criteria: Any condition distorting uterine cavity as myoma, uterine anomalies. Absent fetal pulsations Any condition needing termination of early pregnancy as molar pregnancy or severe deteriorating maternal disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| normal placental site<br>women with normal implantation site at early trimester with normal placental site | Device: Transvaginal ultrasound<br>* transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os<br>|
| Low placental site<br>women with low implantation site at early trimester with low placental site | Device: Transvaginal ultrasound<br>* transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance between the implantation site and the internal cervical os |  | 10 weeks to 40 weeks gestational age | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
implantation site, placental site, Doppler
Monitoring HDR Brachytherapy for Cervical Cancer by Optic and Thermal Imaging

Study Overview
=================
Brief Summary
-----------------
This research aims to investigate the correlation between tumor temperature difference and biological factors, such as size, metabolism, treatment response, and tumor aggressiveness. In addition, normal tissue response to radiation therapy in treated organ will be evaluated.

Official Title
-----------------
Monitoring HDR Brachytherapy for Cervical Cancer by Optic and Thermal Imaging

Conditions
-----------------
MALIGNANCY

Intervention / Treatment
-----------------
* Radiation: THERMOGRAPHY IMAGING


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: signed informed consent biopsy proven cervical cancer which will undergo definitive radiation Exclusion Criteria: not eligible to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients undergoing radiation<br>In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every week during the brachytherapy treatment for 5 procedures | Radiation: THERMOGRAPHY IMAGING<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change in Infra-Red radiation emitted at wavelengths 0.8-1nm | Measurement of IR | Baseline and 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluating of efficacy of the radiation | The thermal and the optic imaging will be taken and analyzed in order to evaluate the changing in the temperature of the cervix comparing to the baseline as the indication of the response to the radiotherapy | 3 months after the treatment |
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.

Official Title
-----------------
A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke.

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Drug: traxiprodil (CP-101,606)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males & females age 40-90 years Enrolled in study within 6 hours of onset of stroke symptoms Willing to sign informed consent form No significant disabilities prior to stroke Exclusion Criteria: Treatment with t-PA (tissue plasminogen activator) Premorbid modified rankin scale score of 2 or more

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: traxiprodil (CP-101,606)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| No or minimal neurological deficit at last visit |  |  | 
| Marked neurological improvement at last visit |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Rankin scale at last visit |  |  | 
| Mortality |  |  | 
| Safety assessments |  |  |
Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia

Study Overview
=================
Brief Summary
-----------------
Lung ultrasonography (LUS) is also used in COVID 19 pneumonia for diagnostic and follow-up purposes.It has been demonstrated in different studies that it can be used for pathologies in pleural and lung tissue. LUS was applied by different researchers by dividing the lungs into 12 and 14 regions and the results were shared.

Detailed Description
-----------------
In our study, we aimed to determine the correlation between lung findings of COVID 19 pneumonia and thoracic tomography with the results of LUS applied to different numbers (12 versus 14) of areas.

Official Title
-----------------
Comparison of Two Different Lung Ultrasound Imaging Protocols in COVID -19 Pneumonia

Conditions
-----------------
Covid19, Lung Ultrasound, Pneumonia

Intervention / Treatment
-----------------
* Device: LUS Twelve area
* Device: LUS Fourteen area


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 and 85 years old Hospitalized in intensive care unit PCR (polymerase chain reaction) tested Thoracic CT applied Exclusion Criteria: Previous lung operation Thoracic wall disorder Interstitial lung disease Patients who did not consent to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: lung ultrasound 12<br>12 zone lung ultrasonography protocol | Device: LUS Twelve area<br>* Application of 12 areas (2 posterior, 2 lateral, and 2 anterior)lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)<br>|
| Active Comparator: lung ultrasound 14<br>14 zone lung ultrasonography protocol | Device: LUS Fourteen area<br>* Application of 14 areas (3 posterior, 2 lateral, and 2 anterior) lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between Thoracic CT imaging results and LUS results | Lung ultrasonography will be performed within 6 hours of the Thoracic CT. | 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characteristics of lesions | Identifying the characteristics of the abnormal findings detected in Thoracic CT and LUS | 6 hours |
Role of New Diagnostic Tool in Device (ICD / PM) Associated Infections

Study Overview
=================
Brief Summary
-----------------
Infections related to implantable pacemakers or cardioverters defibrillators are sometimes difficult to be diagnosed. Diificulties in the diagnosis include a low sensitivity of standard markers of inflammation such as C-reactive protein or white blood cell count and the diagnosis is mainly based on the clinical presentation. The observational DIRT-study evaluates if new biomarkers may be more suitable to support a diagnosis of device associated infections than the currently available ones.

Official Title
-----------------
Device Associated Infections - Role of New Diagnostic Tools

Conditions
-----------------
Biomarkers in Device Associated Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: device associated infections Exclusion Criteria: malignancy cytostatic or immunomodulating therapy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| device associated infection<br>patients with proven device associated infection | |
| control group<br>patients without device associated infection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| procalcitonine | procalcitonine is determined at inclusion and correlated to infectíon status | no follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pacemaker defibrillator infection
MyoSense- Automated Muscle Hypertonicity Classification System

Study Overview
=================
Brief Summary
-----------------
It is often difficult to quantify and distinguish aspects of abnormal muscle tone due to neurological injury. This makes it difficult to evaluate therapies that aim to reduce the effects of abnormal muscle tone. This research study will evaluate the feasibility of a clinician worn device to capture and quantify features of spasticity and dystonia.

Official Title
-----------------
MyoSense- Automated Muscle Hypertonicity Classification System

Conditions
-----------------
Stroke, Dystonia, Cerebral Palsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presentation of dystonia and/or spasticity or, if in control group, no neurological injury nor abnormal muscle tone Over the age of five. Exclusion Criteria: Intolerable pain with manipulation of the knee, ankle, wrist, or elbow Limited range of motion in the knee, ankle, wrist or elbow due to orthopedic injury or severe contraction. Cognitive impairment resulting in inability to provide informed consent or complete the protocol. Under the age of five.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stroke<br>Ten individuals with chronic stroke and limb spasticity will be recruited. | |
| Dystonia<br>Ten individuals with dystonic limbs and no spasticity will be recruited. | |
| Cerebral Palsy<br>Ten individuals with Cerebral palsy with the potential for a mix of dystonic and spastic abnormal tone in their affected limbs will be recruited. | |
| Neurologically normal<br>Thirty individuals without neurological injury that are age matched to the rest of the study population will be recruited. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between clinician and device measured abnormal tone type. | Device measurements of clinician applied force relative to limb manipulation speed will be compared to conventional clinical outcome measures. For example, correlation between the slope of the force to speed profile and clinician evaluated spasticity, Ashworth score, will be calculated. | For each subject clinician and device data will be collected within a single session. Each session will occur over a maximum of two hours. Analysis of all of the subject data will be completed within 30 days of study completion. |
Drug to Drug Interaction Study With ASP1941 and Metformin

Study Overview
=================
Brief Summary
-----------------
A study to investigate the effect on safety, pharmacokinetics and pharmacodynamics when ASP1941 is administered as add-on therapy to metformin.

Official Title
-----------------
A Double-blind, Randomized, Placebo-controlled, Parallel Design Study, in Patients With Type 2 Diabetes Mellitus, to Investigate the Safety, Pharmacokinetics and Pharmacodynamics Interactions of Multiple Oral Doses of ASP1941 and Metformin

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: ASP1941
* Drug: Metformin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with type 2 diabetes Stable disease under metformin monotherapy (between 1500-3000 mg/day) or dual therapy with metformin (1500-3000 mg/day) and a Sulfonylureum Derivative (SUD) for at least 3 months Fasting Serum Glucose: 7-11.5 mmol/l (after wash-out) Stable Fasting Blood Glucose (FBG) at the end of wash-out BMI between 18.5 and 40.0 kg/m2, inclusive Exclusion Criteria: Subjects with type 1 diabetes Any diabetes related macro-complications, painful diabetic neuropathy, diabetic macular edema or diabetic proliferative retinopathy Clinical significant renal disease (CLcr <60 ml/min as assessed during a 24h creatinine clearance on Day-2 Recent evidence (e.g. within the last 6 months) of severe hypoglycemia, for example plasma glucose <3 mmol/l (<55 mg/dl) or requiring hospitalization Pulse <40 or >90; Systolic Blood Pressure >160 mmHg; Diastolic Blood Pressure > 100 mmHg

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ASP1941 + metformin<br>Oral | Drug: ASP1941<br>* Tablet<br>Drug: Metformin<br>* Tablet<br>|
| Placebo Comparator: Placebo + metformin<br>Oral | Drug: Metformin<br>* Tablet<br>Drug: Placebo<br>* Tablet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety assessed by incidence of adverse events, vital signs, 12-lead ECG and glucose monitoring |  | 5 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacodynamics assessed by serum glucose change |  | 5 weeks | 
| Pharmacokinetics assessed by metformin plasma concentration change |  | 5 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pharmacokinetics, metformin, Drug to drug interaction, ASP1941
Acute Kidney Injury in Patients With CoVID-19

Study Overview
=================
Brief Summary
-----------------
We aimed to investigate the effect of Acute Kidney Injury (AKİ) on the prognosis of patients hospitalised for COVID-19.

Detailed Description
-----------------
The effect of Acute Kidney Injury (AKİ) on the prognosis of patients hospitalised for COVID-19. Patients hospitalised for COVID-19 and acute kidney injury will be enrolled. The duration of hospitalisation, mortality rates will be compared in COVID-19 patients with and without acute kidney injury.

Official Title
-----------------
The Effect of Acute Kidney Injury on Prognosis in Patients Hospitalised for COVID-19.

Conditions
-----------------
Covid19, Acute Kidney Injury

Intervention / Treatment
-----------------
* Other: duration of hospitalization, mortality rate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients hospitalised with COVID-19. Patients hospitalised with COVID-19 with Acute Kidney Injury Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 patients with acute kidney injury<br>COVID-19 patients with acute kidney injury | Other: duration of hospitalization, mortality rate<br>* duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.<br>|
| COVID-19 patients without acute kidney injury<br>COVID-19 patients without acute kidney injury | Other: duration of hospitalization, mortality rate<br>* duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality rate | mortality rates of COVID-19 patients with and without Acute Kidney Injury | 6 months | 
| duration of hospitalisation | time between admission to hospital and discharge for COVID-19 patients with and without Acute Kidney Injury | 6 months |
Laryngoscope Prototype Tested Against the Traditional Macintosh Blade

Study Overview
=================
Brief Summary
-----------------
The primary objective is to evaluate a knewly developed blade (for intubating patients about to undergo surgery) and compare it to the traditional Macintosh blade

Detailed Description
-----------------
Intubation of patiens can be difficult, even impossible. It can result in different complications as damage to the teeth, lacerations of the mucosa, bleeding, fractures/luxations, hypoxia, hypercapnia, reflex bradycardia and in worst case braindamage and death. The more difficult the intubation is the more frequent complicationrate. We believe to have developed a laryngoscopeblade that hopefully eases the intubationproces and thereby reduces the complicationrisk. The patients included in this study is patients who are undergoing elective surgery requering intubation.

Conditions
-----------------
Anesthesia, Intravenous

Intervention / Treatment
-----------------
* Device: intubation of patients undergoing elective surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age over 18 ASA 1-III Patients undergoing elective surgery requering intubation at KAS Herlev Exclusion Criteria: Prior difficult intubation indicating awake fiberoptic intubation pathology in the airways predicting difficult intubation columna cervicalis fractures pregnancy Requirement for Rapid sequence induction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: intubation of patients undergoing elective surgery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| succes rate - immediate evaluation |  |  | 
| difficulty - immediate evaluation |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cormack & Lehane grading |  |  | 
| Time to intubate |  |  | 
| Interincissor gap |  |  | 
| vissible complication |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intubation, difficulty, Macintosh, dental damage, complications